SSSuganthi Suppiah

Suganthi Suppiah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Suganthi Suppiah has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Azaibi Tamin

    COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

    1 shared publication
  • Brinda Kamalia

    Department of Biochemistry and Biophysics, University of Pennsylvania , 3620 Hamilton Walk Philadelphia, PA 19104 , USA

    1 shared publication
  • Charles Dusseau

    United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States

    1 shared publication
  • Charles Ogden

    United States Public Health Service, Rockville, MD, United States; Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States

    1 shared publication
  • Christine C. Lee

    Enteric Diseases Laboratory Branch, Centers for Disease Control and Prevention

    1 shared publication
  • Cristen Young

    Bureau of Prisons, U.S. Department of Justice, Washington, DC, United States

    1 shared publication

Latest Publications

  • Open Access

    Nucleoside analogs NM107 and AT-527 are antiviral against rubella virus

    by Mark Dittmar, Kanupriya Whig, Jesse Miller, Brinda Kamalia, Suganthi Suppiah, Ludmila Perelygina, Kathleen E Sullivan, David C Schultz, Sara Cherry

    Rubella is a highly contagious viral infection that usually causes a mild disease in children and adults. However, infection during pregnancy can result in a fetal or newborn death or congenital rubella syndrome (CRS), a constellation of permanent birth defects including cataracts, heart defects, and sensorineural deafness. The live-attenuated rubella vaccine has been highly effective, with the Americas declared free of endemic rubella transmission in 2015. However, rubella remains a significant problem worldwide and the leading cause of vaccine-preventable birth defects globally. Thus, elimination of rubella and CRS is a goal of the World Health Organization. No specific therapeutics are approved for the rubella virus. Therefore, we set out to identify whether existing small molecules may be repurposed for use against rubella virus infection. Thus, we performed a high-throughput screen for small molecules active against rubella virus in human respiratory cells and identified two nucleoside analogs, NM107 and AT-527, with potent antiviral activity. Furthermore, we found that combining these nucleoside analogs with inhibitors of host nucleoside biosynthesis had synergistic antiviral activity. These studies open the door to new potential approaches to treat rubella infections.


  • Open Access

    Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021

    by Phillip P. Salvatore, Christine C. Lee, Sadia Sleweon, David W. McCormick, Lavinia Nicolae, Kristen Knipe, Tom Dixon, Robert Banta, Isaac Ogle, Cristen Young, et al.